Shopping Cart 0
Cart Subtotal
AED 0

Autism Disorder & Treatment Market Information: By Type (Asperger Syndrome, Pervasive Developmental Disorder, Others), by Treatment Type (Aba, Hyperbaric Oxygen Therapy, and Others), by Drug (SSRIs, Anti-Convulsant, Others) - Global Forecast Till 2023

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 16332

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22938
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Autism Disorder & Treatment Market Information: By Type (Asperger Syndrome, Pervasive Developmental Disorder, Others), by Treatment Type (Aba, Hyperbaric Oxygen Therapy, and Others), by Drug (SSRIs, Anti-Convulsant, Others)-Global Forecast Till 2023

Market Analysis

Autism or Autism Spectrum Disorder (ASD)is a type of condition that is caused by major challenges like difficulties with speech, social skills, verbal and nonverbal communication, along with showing the signs of repetitive behaviors and various other strengths and unique differences. This condition is caused by various combinations of hereditary and natural influences. Autism is generally seen in children somewhere under the age group of two to three years. In different cases, it tends to be analyzed within a year or 18 months of birth. Global Autism Disorder & Treatment Market is projected to grow at a CAGR of 4.37% during the forecast period 2017-2023.

Growing awareness about autism amongst the affected population and the increasing prevalence of autism and Pervasive Developmental Disorder (PDD) is boosting the growth of the global autism disorder and treatment market. Autism disorder issue and treatment is seen as one of the prominently developing markets in the healthcare division due to the initiatives and other healthcare activities conducted by the government of different countries and expected endorsements of different off-name treatment treatments by the Food and Drug Association (FDA). With the upsurge in the market, there are a few restraints that are faced by the Global autism disorder & treatment market, for example, a powerless pipeline of drugs for autism disorder and obscure pathophysiology and etiology of ASD.

Market Segmentation

The Global autism disorder & treatment market is classified on the basis of its type, drugs and treatment type. On the basis of its type, the market is segmented into Pervasive Developmental Disorder, Asperger Syndrome, and others. By treatment type, the market is sectioned into hyperbaric oxygen therapy, oxytocin therapy, ABA (applied behavioral analysis), chelation therapy, and others. Based on its drug type, the market is divided into SSRIs, stimulants, anti-convulsant, anti-psychotic.

Regional Analysis

Geographically, the Global autism disorder & treatment market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major Players

Some of the major industry players in the Global autism disorder & treatment market include companies like Pfizer Inc., Allergan, Eli Lilly and Company, Saniona AB, Merck & CO Inc., Consern Pharma Private Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bristol-Myers Squibb and Otsuka Holdings Co., Ltd., Johnson & Johnson Services, Inc., Coronis Partners Ltd., Heptares Therapeutics Limited, Curemark LLC, Intra-Cellular Therapies Inc., among others.

READ MORE

Table Of Content

Scope

Table of Contents:

1 Report Prologue

2 Market Introduction

2.1 Scope of Study

2.2 Research Objective

2.3 Assumptions & Limitations

2.3.1 Assumptions

2.3.2 Limitations

3 Research Methodology

3.1 Primary Research Methodology

3.2 Secondary Research Methodology

3.3 Market Share Analysis

3.4 Trade Analysis

3.5 Market Pricing Approach

4 Market Dynamics

4.1 Introduction

4.2 Drivers

4.2.1 Rising Prevalence of Autism Disorder and Pervasive Developmental Disorder Have Fueled the Growth of the Market.(PDD)

4.2.2 Expected Approvals of Off-Label Drugs to Treat Autism Disorder Has Driven the Market Growth

4.2.3 Rising government or privately held societies taking initiatives to create the awareness about the disease

4.3 Restraints

4.3.1 Weak Product Pipeline of First Drugs for Autism

4.3.2 Unknown Etiology and Pathophysiology of the Disorder Prevent Effective Treatment Options

4.4 Opportunities

4.4.1 Rising Investments by Venture Non-Pharmacology Activities

4.5 Mega Trends

4.6 Macroeconomic Indicators

5 Market Factor Analysis

5.1 Porter's Five Forces Model

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.2.1 R&D

5.2.2 Manufacturing

5.2.3 Distribution & Sales

5.2.4 Post-Sales Monitoring

5.3 Pricing Analysis

5.4 Investment Opportunity Analysis

5.5 Demand & Supply: Gap Analysis

6 Global Autism Disorder & Treatment Market, By Type

6.1 Introduction

6.2 Asperger Syndrome

6.3 Pervasive Developmental Disorders (PDD)

7 Global Autism Disorder & Treatment Market, By Treatment Type

7.1 Introduction

7.2 Expert Opinion: Oxytocin

7.3 ABA (applied behavioral analysis)

7.4 Hyperbaric oxygen therapy

7.5 Chelation therapy

7.6 Oxytocin therapy

8 Global Autism Disorder & Treatment Market, By Drugs

8.1 Introduction

8.2 Selective Serotonin Reuptake Inhibitors (SSRIs)

8.3 Anti-convulsants

8.4 Stimulants

8.5 Anti-psychotic

9 Global Autism Disorder & Treatment Market, By Region

9.1 Introduction

9.2 Americas

9.3 North America

9.3.1 U.S.

9.4 Canada

9.4.1 South America

9.5 Europe

9.5.1 Germany

9.5.2 France

9.5.3 U.K.

9.5.4 Italy

9.5.5 Spain

9.5.6 Rest of Western Europe

9.5.7 Eastern Europe

9.6 Asia Pacific

9.6.1 Japan

9.6.2 China

9.6.3 India

9.6.4 Australia

9.6.5 Republic of Korea

9.6.6 Rest of Asia Pacific

9.7 Middle East & Africa

9.7.1 U.A.E.

9.7.2 Saudi Arabia

9.7.3 Oman

9.7.4 Kuwait

9.7.5 Qatar

9.7.6 Rest of the Middle East & Africa

10 Competitive Landscape

10.1 Company Market Share Analysis

10.1.1 Introduction

10.2 Competitive Landscape

10.2.1 Introduction

10.3 Recent Developments, 2013-2018

11 Company Profiles

11.1 Pfizer Inc.

11.1.1 Company Overview

11.1.2 Financials

11.1.3 Products

11.1.4 Strategy

11.1.5 Key Developments

11.2 Allergan, Plc

11.2.1 Company Overview

11.2.2 Financials

11.2.3 Products

11.2.4 Strategy

11.2.5 Key Developments

11.3 Eli Lilly and Company

11.3.1 Company Overview

11.3.2 Financials

11.3.3 Products

11.3.4 Strategy

11.3.5 Key Developments

11.4 Bristol-Myers Squibb Company

11.4.1 Company Overview

11.4.2 Financials

11.4.3 Products

11.4.4 Strategy

11.4.5 Key Developments

11.5 Sun Pharmaceutical Industries Ltd.

11.5.1 Company Overview

11.5.2 Financials

11.5.3 Products

11.5.4 Strategy

11.5.5 Key Developments

11.6 Johnson & Johnson Services, Inc.

11.6.1 Company Overview

11.6.2 Financials

11.6.3 Products

11.6.4 Strategy

11.6.5 Key Developments

11.7 Teva Pharmaceutical Industries Ltd.

11.7.1 Company Overview

11.7.2 Financials

11.7.3 Products

11.7.4 Strategy

11.7.5 Key Developments

11.8 Merck & Co. Inc

11.8.1 Company Overview

11.8.2 Financials

11.8.3 Products

11.8.4 Strategy

11.8.5 Key Developments

11.9 Novartis AG

11.9.1 Company Overview

11.9.2 Financials

11.9.3 Products

11.9.4 Strategy

11.9.5 Key Developments

11.1 Otsuka Holdings Co. Ltd

11.10.1 Company Overview

11.10.2 Financials

11.10.3 Products

11.10.4 Strategy

11.10.5 Key Developments

11.11 Consern Pharma Private Limited

12 Conclusion

12.1 Key Findings

12.1.1 CEO's Viewpoint

12.1.2 Key Companies to Watch

12.1.3 Prediction of Dietary Supplements in an Age of Personalized Nutrition Industry

13 Appendix

13.1 Discussion Blue Print

13.2 Expert Opinion: Oxytocin

13.3 References


List Of Figure

List of Figures:

FIGURE 1 GLOBAL AUTISM DISORDER & TREATMENT MARKET: MARKET STRUCTURE

FIGURE 2 RESEARCH METHODOLOGY

FIGURE 3 PORTERS FIVE FORCES MODEL

FIGURE 4 VALUE CHAIN: GLOBAL AUTISM DISORDER & TREATMENT MARKET

FIGURE 5 GLOBAL AUTISM DISORDER & TREATMENT, BY TYPE, 2016 & 2023 (USD MILLION)

FIGURE 6 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2016 & 2023 (USD MILLION)

FIGURE 7 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2016 & 2023 (USD MILLION)

FIGURE 8 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY REGION, 2016 & 2023 (USD MILLION)

FIGURE 9 AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY REGION, 2017 (%)

FIGURE 10 EUROPE AUTISM DISORDER & TREATMENT MARKET, BY REGION, 2017 (%)

FIGURE 11 ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2017 (%)

FIGURE 12 MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2017 (%)

FIGURE 13 GLOBAL AUTISM DISORDER & TREATMENT MARKET, COMPANY SHARE ANALYSIS 2016 (%)

FIGURE 14 GLOBAL AUTISM DISORDER & TREATMENT MARKET COMPETITIVE LANDSCAPE 2016 (%)


List Of Table

List of Tables:

TABLE 1 MARKET SYNOPSIS

TABLE 2 PRIMARY INTERVIEWS

TABLE 3 GLOBAL AUTISM DISORDER & TREATMENT, BY TYPE, 2014-2023, (USD MILLION)

TABLE 4 GLOBAL AUTISM DISORDER & TREATMENT FOR ASPERGER SYNDROME , BY REGION, 2014-2023, (USD MILLION)

TABLE 5 GLOBAL AUTISM DISORDER & TREATMENT FOR PERVASIVE DEVELOPMENTAL DISORDER, BY REGION, 2014-2023 (USD MILLION)

TABLE 6 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 7 GLOBAL AUTISM DISORDER & TREATMENT FOR ABA (APPLIED BEHAVIORAL ANALYSIS), BY REGION, 2014-2023, (USD MILLION)

TABLE 8 GLOBAL AUTISM DISORDER & TREATMENT FOR HYPERBARIC OXYGEN THERAPY, BY REGION, 2014-2023, (USD MILLION)

TABLE 9 GLOBAL AUTISM DISORDER & TREATMENT FOR CHELATION THERAPY, BY REGION, 2014-2023, (USD MILLION)

TABLE 10 GLOBAL AUTISM DISORDER & TREATMENT FOR OXYTOCIN THERAPY, BY REGION, 2014-2023, (USD MILLION)

TABLE 11 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 12 GLOBAL AUTISM DISORDER & TREATMENT FOR SSRIS, BY REGION, 2014-2023, (USD MILLION)

TABLE 13 GLOBAL AUTISM DISORDER & TREATMENT FOR ANTI-CONVULSANTS, BY REGION, 2014-2023, (USD MILLION)

TABLE 14 GLOBAL AUTISM DISORDER & TREATMENT FOR STIMULANTS, BY REGION, 2014-2023, (USD MILLION)

TABLE 15 GLOBAL AUTISM DISORDER & TREATMENT FOR ANTI-PSYCHOTIC, BY REGION, 2014-2023, (USD MILLION)

TABLE 16 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY REGION, 2014-2023, (USD MILLION)

TABLE 17 AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2014-2023, (USD MILLION)

TABLE 18 AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 19 AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 20 AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 21 U.S. AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 22 U.S. AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 23 U.S. AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 24 CANADA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 25 CANADA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 26 CANADA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 27 SOUTH AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 28 SOUTH AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 29 SOUTH AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 30 EUROPE AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2014-2023, (USD MILLION)

TABLE 31 EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 32 EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 33 EUROPE AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 34 GERMANY AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 35 GERMANY AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 36 GERMANY AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 37 FRANCE AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 38 FRANCE AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 39 FRANCE AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 40 U.K. AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 41 U.K. AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 42 U.K. AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 43 ITALY AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 44 ITALY AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 45 ITALY AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 46 SPAIN AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 47 SPAIN AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 48 SPAIN AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 49 REST OF WESTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 50 REST OF WESTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 51 REST OF WESTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 52 EASTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 53 EASTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 54 EASTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 55 ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2014-2023, (USD MILLION)

TABLE 56 ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 57 ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 58 ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 59 JAPAN AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 60 JAPAN AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 61 JAPAN AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 62 CHINA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 63 CHINA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 64 CHINA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 65 INDIA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 66 INDIA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 67 INDIA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 68 AUSTRALIA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 69 AUSTRALIA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 70 AUSTRALIA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 71 REPUBLIC OF KOREA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 72 REPUBLIC OF KOREA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 73 REPUBLIC OF KOREA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 74 REST OF ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 75 REST OF ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 76 REST OF ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 77 MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2014-2023, (USD MILLION)

TABLE 78 MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 79 MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 80 MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 81 U.A.E. AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 82 U.A.E. AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 83 U.A.E. AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 84 SAUDI ARABIA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 85 SAUDI ARABIA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 86 SAUDI ARABIA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 87 OMAN AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 88 OMAN AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 89 OMAN AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 90 KUWAIT AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 91 KUWAIT AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 92 KUWAIT AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 93 QATAR AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 94 QATAR AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 95 QATAR AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 96 REST OF MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 97 REST OF MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 98 REST OF MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

Licence Rights

"Single User License: OnIine PDF View Only
Enterprise-user License : Print & download option is available."

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Pfizer Inc., Allergan, Eli Lilly and Company, Saniona AB, Merck & CO Inc., Consern Pharma Private Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bristol-Myers Squibb and Otsuka Holdings Co., Ltd., Johnson & Johnson Services, Inc., Coronis Partners Ltd., Heptares Therapeutics Limited, Curemark LLC, Intra-Cellular Therapies Inc., among others

Autism Disorder & Treatment Market Information: By Type (Asperger Syndrome, Pervasive Developmental Disorder, Others), by Treatment Type (Aba, Hyperbaric Oxygen Therapy, and Others), by Drug (SSRIs, Anti-Convulsant, Others)-Global Forecast Till 2023

Market Analysis

Autism or Autism Spectrum Disorder (ASD)is a type of condition that is caused by major challenges like difficulties with speech, social skills, verbal and nonverbal communication, along with showing the signs of repetitive behaviors and various other strengths and unique differences. This condition is caused by various combinations of hereditary and natural influences. Autism is generally seen in children somewhere under the age group of two to three years. In different cases, it tends to be analyzed within a year or 18 months of birth. Global Autism Disorder & Treatment Market is projected to grow at a CAGR of 4.37% during the forecast period 2017-2023.

Growing awareness about autism amongst the affected population and the increasing prevalence of autism and Pervasive Developmental Disorder (PDD) is boosting the growth of the global autism disorder and treatment market. Autism disorder issue and treatment is seen as one of the prominently developing markets in the healthcare division due to the initiatives and other healthcare activities conducted by the government of different countries and expected endorsements of different off-name treatment treatments by the Food and Drug Association (FDA). With the upsurge in the market, there are a few restraints that are faced by the Global autism disorder & treatment market, for example, a powerless pipeline of drugs for autism disorder and obscure pathophysiology and etiology of ASD.

Market Segmentation

The Global autism disorder & treatment market is classified on the basis of its type, drugs and treatment type. On the basis of its type, the market is segmented into Pervasive Developmental Disorder, Asperger Syndrome, and others. By treatment type, the market is sectioned into hyperbaric oxygen therapy, oxytocin therapy, ABA (applied behavioral analysis), chelation therapy, and others. Based on its drug type, the market is divided into SSRIs, stimulants, anti-convulsant, anti-psychotic.

Regional Analysis

Geographically, the Global autism disorder & treatment market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major Players

Some of the major industry players in the Global autism disorder & treatment market include companies like Pfizer Inc., Allergan, Eli Lilly and Company, Saniona AB, Merck & CO Inc., Consern Pharma Private Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bristol-Myers Squibb and Otsuka Holdings Co., Ltd., Johnson & Johnson Services, Inc., Coronis Partners Ltd., Heptares Therapeutics Limited, Curemark LLC, Intra-Cellular Therapies Inc., among others.

READ MORE

Scope

Table of Contents:

1 Report Prologue

2 Market Introduction

2.1 Scope of Study

2.2 Research Objective

2.3 Assumptions & Limitations

2.3.1 Assumptions

2.3.2 Limitations

3 Research Methodology

3.1 Primary Research Methodology

3.2 Secondary Research Methodology

3.3 Market Share Analysis

3.4 Trade Analysis

3.5 Market Pricing Approach

4 Market Dynamics

4.1 Introduction

4.2 Drivers

4.2.1 Rising Prevalence of Autism Disorder and Pervasive Developmental Disorder Have Fueled the Growth of the Market.(PDD)

4.2.2 Expected Approvals of Off-Label Drugs to Treat Autism Disorder Has Driven the Market Growth

4.2.3 Rising government or privately held societies taking initiatives to create the awareness about the disease

4.3 Restraints

4.3.1 Weak Product Pipeline of First Drugs for Autism

4.3.2 Unknown Etiology and Pathophysiology of the Disorder Prevent Effective Treatment Options

4.4 Opportunities

4.4.1 Rising Investments by Venture Non-Pharmacology Activities

4.5 Mega Trends

4.6 Macroeconomic Indicators

5 Market Factor Analysis

5.1 Porter's Five Forces Model

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.2.1 R&D

5.2.2 Manufacturing

5.2.3 Distribution & Sales

5.2.4 Post-Sales Monitoring

5.3 Pricing Analysis

5.4 Investment Opportunity Analysis

5.5 Demand & Supply: Gap Analysis

6 Global Autism Disorder & Treatment Market, By Type

6.1 Introduction

6.2 Asperger Syndrome

6.3 Pervasive Developmental Disorders (PDD)

7 Global Autism Disorder & Treatment Market, By Treatment Type

7.1 Introduction

7.2 Expert Opinion: Oxytocin

7.3 ABA (applied behavioral analysis)

7.4 Hyperbaric oxygen therapy

7.5 Chelation therapy

7.6 Oxytocin therapy

8 Global Autism Disorder & Treatment Market, By Drugs

8.1 Introduction

8.2 Selective Serotonin Reuptake Inhibitors (SSRIs)

8.3 Anti-convulsants

8.4 Stimulants

8.5 Anti-psychotic

9 Global Autism Disorder & Treatment Market, By Region

9.1 Introduction

9.2 Americas

9.3 North America

9.3.1 U.S.

9.4 Canada

9.4.1 South America

9.5 Europe

9.5.1 Germany

9.5.2 France

9.5.3 U.K.

9.5.4 Italy

9.5.5 Spain

9.5.6 Rest of Western Europe

9.5.7 Eastern Europe

9.6 Asia Pacific

9.6.1 Japan

9.6.2 China

9.6.3 India

9.6.4 Australia

9.6.5 Republic of Korea

9.6.6 Rest of Asia Pacific

9.7 Middle East & Africa

9.7.1 U.A.E.

9.7.2 Saudi Arabia

9.7.3 Oman

9.7.4 Kuwait

9.7.5 Qatar

9.7.6 Rest of the Middle East & Africa

10 Competitive Landscape

10.1 Company Market Share Analysis

10.1.1 Introduction

10.2 Competitive Landscape

10.2.1 Introduction

10.3 Recent Developments, 2013-2018

11 Company Profiles

11.1 Pfizer Inc.

11.1.1 Company Overview

11.1.2 Financials

11.1.3 Products

11.1.4 Strategy

11.1.5 Key Developments

11.2 Allergan, Plc

11.2.1 Company Overview

11.2.2 Financials

11.2.3 Products

11.2.4 Strategy

11.2.5 Key Developments

11.3 Eli Lilly and Company

11.3.1 Company Overview

11.3.2 Financials

11.3.3 Products

11.3.4 Strategy

11.3.5 Key Developments

11.4 Bristol-Myers Squibb Company

11.4.1 Company Overview

11.4.2 Financials

11.4.3 Products

11.4.4 Strategy

11.4.5 Key Developments

11.5 Sun Pharmaceutical Industries Ltd.

11.5.1 Company Overview

11.5.2 Financials

11.5.3 Products

11.5.4 Strategy

11.5.5 Key Developments

11.6 Johnson & Johnson Services, Inc.

11.6.1 Company Overview

11.6.2 Financials

11.6.3 Products

11.6.4 Strategy

11.6.5 Key Developments

11.7 Teva Pharmaceutical Industries Ltd.

11.7.1 Company Overview

11.7.2 Financials

11.7.3 Products

11.7.4 Strategy

11.7.5 Key Developments

11.8 Merck & Co. Inc

11.8.1 Company Overview

11.8.2 Financials

11.8.3 Products

11.8.4 Strategy

11.8.5 Key Developments

11.9 Novartis AG

11.9.1 Company Overview

11.9.2 Financials

11.9.3 Products

11.9.4 Strategy

11.9.5 Key Developments

11.1 Otsuka Holdings Co. Ltd

11.10.1 Company Overview

11.10.2 Financials

11.10.3 Products

11.10.4 Strategy

11.10.5 Key Developments

11.11 Consern Pharma Private Limited

12 Conclusion

12.1 Key Findings

12.1.1 CEO's Viewpoint

12.1.2 Key Companies to Watch

12.1.3 Prediction of Dietary Supplements in an Age of Personalized Nutrition Industry

13 Appendix

13.1 Discussion Blue Print

13.2 Expert Opinion: Oxytocin

13.3 References


List Of Figure

List of Figures:

FIGURE 1 GLOBAL AUTISM DISORDER & TREATMENT MARKET: MARKET STRUCTURE

FIGURE 2 RESEARCH METHODOLOGY

FIGURE 3 PORTERS FIVE FORCES MODEL

FIGURE 4 VALUE CHAIN: GLOBAL AUTISM DISORDER & TREATMENT MARKET

FIGURE 5 GLOBAL AUTISM DISORDER & TREATMENT, BY TYPE, 2016 & 2023 (USD MILLION)

FIGURE 6 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2016 & 2023 (USD MILLION)

FIGURE 7 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2016 & 2023 (USD MILLION)

FIGURE 8 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY REGION, 2016 & 2023 (USD MILLION)

FIGURE 9 AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY REGION, 2017 (%)

FIGURE 10 EUROPE AUTISM DISORDER & TREATMENT MARKET, BY REGION, 2017 (%)

FIGURE 11 ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2017 (%)

FIGURE 12 MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2017 (%)

FIGURE 13 GLOBAL AUTISM DISORDER & TREATMENT MARKET, COMPANY SHARE ANALYSIS 2016 (%)

FIGURE 14 GLOBAL AUTISM DISORDER & TREATMENT MARKET COMPETITIVE LANDSCAPE 2016 (%)


List Of Table

List of Tables:

TABLE 1 MARKET SYNOPSIS

TABLE 2 PRIMARY INTERVIEWS

TABLE 3 GLOBAL AUTISM DISORDER & TREATMENT, BY TYPE, 2014-2023, (USD MILLION)

TABLE 4 GLOBAL AUTISM DISORDER & TREATMENT FOR ASPERGER SYNDROME , BY REGION, 2014-2023, (USD MILLION)

TABLE 5 GLOBAL AUTISM DISORDER & TREATMENT FOR PERVASIVE DEVELOPMENTAL DISORDER, BY REGION, 2014-2023 (USD MILLION)

TABLE 6 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 7 GLOBAL AUTISM DISORDER & TREATMENT FOR ABA (APPLIED BEHAVIORAL ANALYSIS), BY REGION, 2014-2023, (USD MILLION)

TABLE 8 GLOBAL AUTISM DISORDER & TREATMENT FOR HYPERBARIC OXYGEN THERAPY, BY REGION, 2014-2023, (USD MILLION)

TABLE 9 GLOBAL AUTISM DISORDER & TREATMENT FOR CHELATION THERAPY, BY REGION, 2014-2023, (USD MILLION)

TABLE 10 GLOBAL AUTISM DISORDER & TREATMENT FOR OXYTOCIN THERAPY, BY REGION, 2014-2023, (USD MILLION)

TABLE 11 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 12 GLOBAL AUTISM DISORDER & TREATMENT FOR SSRIS, BY REGION, 2014-2023, (USD MILLION)

TABLE 13 GLOBAL AUTISM DISORDER & TREATMENT FOR ANTI-CONVULSANTS, BY REGION, 2014-2023, (USD MILLION)

TABLE 14 GLOBAL AUTISM DISORDER & TREATMENT FOR STIMULANTS, BY REGION, 2014-2023, (USD MILLION)

TABLE 15 GLOBAL AUTISM DISORDER & TREATMENT FOR ANTI-PSYCHOTIC, BY REGION, 2014-2023, (USD MILLION)

TABLE 16 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY REGION, 2014-2023, (USD MILLION)

TABLE 17 AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2014-2023, (USD MILLION)

TABLE 18 AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 19 AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 20 AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 21 U.S. AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 22 U.S. AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 23 U.S. AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 24 CANADA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 25 CANADA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 26 CANADA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 27 SOUTH AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 28 SOUTH AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 29 SOUTH AMERICAS AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 30 EUROPE AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2014-2023, (USD MILLION)

TABLE 31 EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 32 EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 33 EUROPE AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 34 GERMANY AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 35 GERMANY AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 36 GERMANY AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 37 FRANCE AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 38 FRANCE AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 39 FRANCE AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 40 U.K. AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 41 U.K. AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 42 U.K. AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 43 ITALY AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 44 ITALY AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 45 ITALY AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 46 SPAIN AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 47 SPAIN AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 48 SPAIN AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 49 REST OF WESTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 50 REST OF WESTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 51 REST OF WESTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 52 EASTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 53 EASTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 54 EASTERN EUROPE AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 55 ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2014-2023, (USD MILLION)

TABLE 56 ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 57 ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 58 ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 59 JAPAN AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 60 JAPAN AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 61 JAPAN AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 62 CHINA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 63 CHINA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 64 CHINA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 65 INDIA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 66 INDIA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 67 INDIA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 68 AUSTRALIA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 69 AUSTRALIA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 70 AUSTRALIA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 71 REPUBLIC OF KOREA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 72 REPUBLIC OF KOREA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 73 REPUBLIC OF KOREA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 74 REST OF ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 75 REST OF ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 76 REST OF ASIA PACIFIC AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 77 MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY COUNTRY, 2014-2023, (USD MILLION)

TABLE 78 MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 79 MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 80 MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 81 U.A.E. AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 82 U.A.E. AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 83 U.A.E. AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 84 SAUDI ARABIA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 85 SAUDI ARABIA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 86 SAUDI ARABIA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 87 OMAN AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 88 OMAN AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 89 OMAN AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 90 KUWAIT AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 91 KUWAIT AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 92 KUWAIT AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 93 QATAR AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 94 QATAR AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 95 QATAR AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

TABLE 96 REST OF MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY TYPE, 2014-2023, (USD MILLION)

TABLE 97 REST OF MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE, 2014-2023, (USD MILLION)

TABLE 98 REST OF MIDDLE EAST & AFRICA AUTISM DISORDER & TREATMENT MARKET, BY DRUGS, 2014-2023, (USD MILLION)

"Single User License: OnIine PDF View Only
Enterprise-user License : Print & download option is available."

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Pfizer Inc., Allergan, Eli Lilly and Company, Saniona AB, Merck & CO Inc., Consern Pharma Private Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Bristol-Myers Squibb and Otsuka Holdings Co., Ltd., Johnson & Johnson Services, Inc., Coronis Partners Ltd., Heptares Therapeutics Limited, Curemark LLC, Intra-Cellular Therapies Inc., among others